Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.
Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| aged ≥ 45 years with haematuria scheduled for cystoscopy, for suspicion of urothelial carcinoma | Adult participants aged ≥ 45 years presenting with haematuria in the past 6 months, scheduled to undergo haematuria workup, including cystoscopy, for suspicion of urothelial carcinoma. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bladder EpiCheck | Diagnostic Test | The participant will provide a voided urine sample, which will be tested using the Bladder EpiCheck test. The clinical care team and the participant will not be informed of the result, and the standard of care will not change. |
| Measure | Description | Time Frame |
|---|---|---|
| The sensitivity and specificity of Bladder EpiCheck to detect primary urothelial carcinoma | The sensitivity and specificity of Bladder EpiCheck to detect primary urothelial carcinoma, calculated versus the Reference Standard defined by cystoscopy, imaging, and, if indicated, pathological confirmation) in participants presenting with haematuria (visible and/or non-visible). | urothelial carcinoma detected within 6 months of enrolment, by the standard of care haematuria work-up |
| Measure | Description | Time Frame |
|---|---|---|
| Non-inferiority of Bladder EpiCheck overall sensitivity vs. cytology in detection of primary urothelial carcinoma | urothelial carcinoma detected within 6 months of enrolment, by the standard of care haematuria work-up | |
| Non-inferiority of Bladder EpiCheck specificity vs. cytology in detection of primary urothelial carcinoma |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
aged ≥ 45 years with haematuria scheduled for cystoscopy, for suspicion of urothelial carcinoma
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Vered Yayon | Contact | +972-8-9161616 | vered.y@nucleix.com | |
| Admin. | Contact | info@nucleix.com |
| Name | Affiliation | Role |
|---|---|---|
| Paramananthan Mariappan, MB BS PhD FRCS(Urol) FEBU FRCS | Western General Hospital, Edinburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NHS Fife | Recruiting | Dunfermline | Fife | KY12 OSU | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31100252 | Result | Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, Sternberg IA, Willemsen E, Hegemann ML, Paitan Y, Leibovitch I. Performance of the Bladder EpiCheck Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur Urol Oncol. 2018 Sep;1(4):307-313. doi: 10.1016/j.euo.2018.06.011. Epub 2018 Jul 17. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006417 | Hematuria |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
Not provided
Not provided
Not provided
voided urine
| urothelial carcinoma detected within 6 months of enrolment, by the standard of care haematuria work-up |
| Further validate the sensitivity of the Bladder EpiCheck test to detect pathologically confirmed high-grade urothelial carcinoma, including HG non-muscle invasive and muscle invasive disease. | urothelial carcinoma detected within 6 months of enrolment, by the standard of care haematuria work-up |
| Addenbrooke's Hospital | Recruiting | Cambridge | United Kingdom |
|
| NHS Lothian | Recruiting | Edinburgh | United Kingdom |
|
| Guy's and St Thomas | Recruiting | London | United Kingdom |
|
| Frimley | Recruiting | Surrey Quays | United Kingdom |
|
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |